Oval Advanced Fertility Care and Merck Specialities, an Indian healthcare arm of Merck KGaA, entered into a Memorandum of Understanding (MoU) to strengthen clinical capabilities, to improve transparency and patient experience through technology and data-led approaches.
“The partnership with Merck brings together shared values around transparency, clinical excellence, and putting the patient at the centre of every decision,” Veena Reddy, co-founder & director, Oval Fertility said in a release.
Pratima Reddy, Managing Director, Merck Specialities, said, “Fertility care in India is evolving rapidly, with patients seeking greater transparency, a more seamless experience and stronger confidence in outcomes. Merck is well positioned to partner with progressive care providers to address these expectations through an integrated approach,”
India’s IVF market, valued at approximately $2.35 billion in 2024, is projected to reach $5.03 billion by 2034, growing at a compound annual growth rate of 7.9 per cent, the release added.
Published on June 11, 2026
